80066-70-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Isoquinolinecarboxylic acid, 5-amino-, methylester (9CI) is used as a key intermediate in the synthesis of antipsychotic and antimalarial drugs. Its unique structure allows for the development of new medications with improved efficacy and reduced side effects.
Used in Organic Chemistry:
3-Isoquinolinecarboxylic acid, 5-amino-, methylester (9CI) serves as a building block in the production of various organic compounds. Its versatile chemical properties enable the creation of a wide range of molecules with different applications in various industries.
Used in Medicinal Chemistry and Drug Development:
Due to its structural properties and pharmacological activities, 3-Isoquinolinecarboxylic acid, 5-amino-, methylester (9CI) has potential applications in medicinal chemistry and drug development. Researchers can utilize 3-Isoquinolinecarboxylicacid,5-amino-,methylester(9CI) to design and develop new drugs with targeted therapeutic effects and improved safety profiles.

Upstream product

• 581812-72-8 Methyl 5-nitroisoquinoline-3-carboxylate 
• 27104-73-0 methyl isoquinoline-3-carboxylate 
• 80066-71-3 5-aminoisoquinoline-3-carboxylic acid 
• 7439-89-6 iron 

Downstream Products

• 1005029-80-0 methyl 5-iodoisoquinoline-3-carboxylate 

Relevant academic research and scientific papers

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Thiazolo[3,4-b]isoquinolines

Isoquinoline derivatives of the formula STR1 wherein the symbol A1 represents an isoquinol-8-yl, 3-methylisoquinol-8-yl, 3-hydroxymethylisoquinol-5-yl, 3-carboxymethylisoquinol-5-yl, quinol-5-yl, thienopyridyl, benzimidazolyl, thienyl or thiazolyl radical, a 4-(or 5-)carboxyalkylthiazol-2-yl radical in which the alkyl moiety is linear or branched and contains 1 to 4 carbon atoms, or a 1,3,4-thiadiazol-2-yl, pyrazolyl, imidazolyl, pyrimidinyl, pyridazinyl or pyrazinyl radical, monocyclic heterocyclic rings within the definition of A1 being optionally substituted by a linear or branched alkyl radical containing 1 to 4 carbon atoms, in the (S) or (R,S) form or mixtures thereof, and salts thereof possess useful pharmocological properties, in particular antiviral activity.